NASDAQ:MBX MBX Biosciences (MBX) Stock Price, News & Analysis $62.91 -0.98 (-1.53%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$62.87 -0.04 (-0.06%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About MBX Biosciences Stock (NASDAQ:MBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MBX Biosciences alerts:Sign Up Key Stats Today's Range$61.40▼$64.0550-Day Range$56.59▼$70.7052-Week Range$9.66▼$72.64Volume932,361 shsAverage Volume418,007 shsMarket Capitalization$3.03 billionP/E RatioN/ADividend YieldN/APrice Target$77.00Consensus RatingModerate Buy Company Overview MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. The company uses its Precision Empowered Peptide platform to design peptide medicines intended to provide targeted biological activity, extended duration and improved dosing convenience. MBX’s lead product candidate is MBX 2109, an investigational long-acting parathyroid hormone replacement therapy being developed for people with hypoparathyroidism. The company is also advancing additional peptide-based candidates intended to address significant unmet needs in endocrine and metabolic disease. Founded in 2018 and headquartered in Indianapolis, Indiana, MBX Biosciences conducts research and clinical development primarily in the United States. Its programs remain investigational and have not been approved for commercial use by the U.S. Food and Drug Administration or other regulatory authorities.AI Generated. May Contain Errors. Read More MBX Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreMBX MarketRank™: MBX Biosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 549th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingMBX Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialMBX Biosciences has a consensus price target of $77.00, representing about 22.4% upside from its current price of $62.91.Amount of Analyst CoverageMBX Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MBX Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MBX Biosciences are expected to decrease in the coming year, from ($3.04) to ($3.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MBX Biosciences is -26.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MBX Biosciences is -26.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMBX Biosciences has a P/B Ratio of 7.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.52% of the float of MBX Biosciences has been sold short.Short Interest Ratio / Days to CoverMBX Biosciences has a short interest ratio ("days to cover") of 10.14, which indicates bearish sentiment.Change versus previous monthShort interest in MBX Biosciences has recently decreased by 16.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMBX Biosciences does not currently pay a dividend.Dividend GrowthMBX Biosciences does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.45 News SentimentMBX Biosciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MBX Biosciences this week, compared to 4 articles on an average week.Search Interest5 people have searched for MBX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MBX Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,335.00 in company stock.Percentage Held by Insiders31.09% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsMBX Biosciences has minimal institutional ownership at this time.Read more about MBX Biosciences' insider trading history. Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBX Stock News HeadlinesMBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 17 at 2:44 AM | americanbankingnews.comMBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16 at 4:00 PM | seekingalpha.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 19 at 1:00 AM | The Oxford Club (Ad)MBX Biosciences to Participate in Upcoming Investor ConferencesSeptember 9, 2026 | globenewswire.comMBX Biosciences Announces Appointment of Jeff Held as Chief Legal OfficerSeptember 8, 2026 | globenewswire.comMBX Biosciences Begins Pivotal Phase 3 Canvuparatide TrialAugust 27, 2026 | tipranks.comMBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with HypoparathyroidismAugust 27, 2026 | globenewswire.comMBX Biosciences, Inc. (MBX) Gets a Buy from Mizuho SecuritiesAugust 10, 2026 | theglobeandmail.comSee More Headlines MBX Stock Analysis - Frequently Asked Questions How have MBX shares performed this year? MBX Biosciences' stock was trading at $31.54 at the start of the year. Since then, MBX stock has increased by 99.5% and is now trading at $62.91. How were MBX Biosciences' earnings last quarter? MBX Biosciences, Inc. (NASDAQ:MBX) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.10. When did MBX Biosciences IPO? MBX Biosciences (MBX) raised $153 million in an IPO on Thursday, September 12th 2024. The company issued 10,200,000 shares at $14.00-$16.00 per share. Who are MBX Biosciences' major shareholders? MBX Biosciences' top institutional investors include Wellington Management Group LLP (10.34%), BlackRock Inc. (6.98%), Parkman Healthcare Partners LLC (1.66%) and Braidwell LP (1.48%). Insiders that own company stock include Patrick J Heron, Life Sciences X LP Frazier, Edward T Mathers, Carl L Gordon, P Kent Hawryluk, Ora H Pescovitz, Steven L Hoerter and Salomon Azoulay. View institutional ownership trends. How do I buy shares of MBX Biosciences? Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today9/19/2026Stifel 2026 Virtual Cardiometabolic Forum9/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MBX's financial health is in the Green zone, according to TradeSmith. MBX has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MBX Previous SymbolNASDAQ:MBX CIK1776111 Webmbxbio.com Phone(317) 989-3100FaxN/AEmployees63Year Founded2018Price Target and Rating Average Price Target for MBX Biosciences$77.00 High Price Target$91.00 Low Price Target$18.00 Potential Upside/Downside+22.4%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$86.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.02% Return on Assets-24.94% Debt Debt-to-Equity RatioN/A Current Ratio18.08 Quick Ratio18.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book7.65Miscellaneous Outstanding Shares48,160,000Free Float33,187,000Market Cap$3.03 billion OptionableN/A Beta0.04 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MBX) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
